JP2020534313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534313A5 JP2020534313A5 JP2020516552A JP2020516552A JP2020534313A5 JP 2020534313 A5 JP2020534313 A5 JP 2020534313A5 JP 2020516552 A JP2020516552 A JP 2020516552A JP 2020516552 A JP2020516552 A JP 2020516552A JP 2020534313 A5 JP2020534313 A5 JP 2020534313A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell composition
- composition according
- isolated cell
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 125
- 210000001744 T-lymphocyte Anatomy 0.000 claims 50
- 239000000427 antigen Substances 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 239000012636 effector Substances 0.000 claims 17
- 108090000978 Interleukin-4 Proteins 0.000 claims 9
- 108090001005 Interleukin-6 Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000005291 magnetic effect Effects 0.000 claims 6
- 108010002350 Interleukin-2 Proteins 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 4
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- -1 IL-1β Proteins 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000011712 cell development Effects 0.000 claims 3
- 108010074108 interleukin-21 Proteins 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102000008160 Cyclin A1 Human genes 0.000 claims 2
- 108010060267 Cyclin A1 Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 102100034681 Myeloblastin Human genes 0.000 claims 2
- 102000036673 PRAME Human genes 0.000 claims 2
- 108060006580 PRAME Proteins 0.000 claims 2
- 102000000763 Survivin Human genes 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 244000053095 fungal pathogen Species 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- 244000052613 viral pathogen Species 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561044P | 2017-09-20 | 2017-09-20 | |
| US62/561,044 | 2017-09-20 | ||
| US201862656679P | 2018-04-12 | 2018-04-12 | |
| US62/656,679 | 2018-04-12 | ||
| PCT/US2018/051971 WO2019060558A1 (en) | 2017-09-20 | 2018-09-20 | CELLULAR COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534313A JP2020534313A (ja) | 2020-11-26 |
| JP2020534313A5 true JP2020534313A5 (enExample) | 2021-10-14 |
| JP7475684B2 JP7475684B2 (ja) | 2024-04-30 |
Family
ID=65810886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516552A Active JP7475684B2 (ja) | 2017-09-20 | 2018-09-20 | 養子療法のための抗原特異的ｔ細胞を含む細胞組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190119639A1 (enExample) |
| EP (1) | EP3684402A4 (enExample) |
| JP (1) | JP7475684B2 (enExample) |
| KR (1) | KR102850471B1 (enExample) |
| CN (1) | CN111629748A (enExample) |
| AU (1) | AU2018337960B2 (enExample) |
| BR (1) | BR112020005552A2 (enExample) |
| CA (1) | CA3076490A1 (enExample) |
| IL (1) | IL273452B2 (enExample) |
| MX (1) | MX2020003129A (enExample) |
| RU (1) | RU2020113627A (enExample) |
| SG (1) | SG11202002523YA (enExample) |
| WO (1) | WO2019060558A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1814580T3 (en) | 2004-11-24 | 2016-12-12 | Hutchinson Fred Cancer Res | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| CN120519386A (zh) | 2017-11-08 | 2025-08-22 | 百欧恩泰美国公司 | T细胞制备组合物和方法 |
| US20220016166A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | T-cell expressing chimeric receptor |
| US20200188435A1 (en) * | 2018-11-08 | 2020-06-18 | Nexlmmune, Inc. | T cell compositions with improved phenotypic properties |
| TWI867324B (zh) * | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| BR112022021551A2 (pt) | 2020-04-28 | 2023-01-03 | Lyell Immunopharma Inc | Métodos para cultivar células |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| WO2022234856A1 (ja) * | 2021-05-07 | 2022-11-10 | 康人 徳元 | メモリーｔ細胞の製造方法 |
| CN113945715B (zh) * | 2021-08-30 | 2023-04-21 | 四川大学华西医院 | 供者特异性IL-21和IFN-γ的检测方法及应用 |
| EP4463542A1 (en) * | 2022-02-15 | 2024-11-20 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US20050169898A1 (en) * | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
| KR102073901B1 (ko) * | 2011-09-08 | 2020-02-05 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도 |
| WO2014039044A1 (en) * | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| WO2014209868A1 (en) | 2013-06-24 | 2014-12-31 | Neximmune | Compositions and methods for immunotherapy |
| CA2961749C (en) * | 2014-09-17 | 2021-01-12 | The Johns Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| EP3034092A1 (en) * | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| MX391015B (es) | 2014-12-24 | 2025-03-21 | Neximmune Inc | Composiciones de nanoparticulas y usos de las mismas |
| MA44314A (fr) | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées |
| TW201621210A (zh) * | 2016-02-26 | 2016-06-16 | Liquidleds Lighting Corp | 發光二極體光源及燈具 |
| AU2017233035B2 (en) * | 2016-03-16 | 2021-08-05 | Neximmune, Inc. | Production of antigen-specific T-cells |
-
2018
- 2018-09-20 CN CN201880074419.8A patent/CN111629748A/zh active Pending
- 2018-09-20 RU RU2020113627A patent/RU2020113627A/ru unknown
- 2018-09-20 EP EP18859009.5A patent/EP3684402A4/en active Pending
- 2018-09-20 CA CA3076490A patent/CA3076490A1/en active Pending
- 2018-09-20 KR KR1020207011215A patent/KR102850471B1/ko active Active
- 2018-09-20 JP JP2020516552A patent/JP7475684B2/ja active Active
- 2018-09-20 BR BR112020005552-2A patent/BR112020005552A2/pt unknown
- 2018-09-20 IL IL273452A patent/IL273452B2/en unknown
- 2018-09-20 US US16/136,931 patent/US20190119639A1/en not_active Abandoned
- 2018-09-20 MX MX2020003129A patent/MX2020003129A/es unknown
- 2018-09-20 WO PCT/US2018/051971 patent/WO2019060558A1/en not_active Ceased
- 2018-09-20 AU AU2018337960A patent/AU2018337960B2/en active Active
- 2018-09-20 SG SG11202002523YA patent/SG11202002523YA/en unknown
-
2022
- 2022-11-18 US US17/989,905 patent/US20230399613A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534313A5 (enExample) | ||
| RU2020113627A (ru) | Композиции клеток, содержащие антигенспецифические т-клетки, для адоптивной терапии | |
| Baxevanis et al. | Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor | |
| Kalinski et al. | Dendritic cell-based therapeutic cancer vaccines: what we have and what we need | |
| Butler et al. | Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell | |
| AU2015311761B2 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| US11027001B2 (en) | Therapeutic cancer vaccines derived from a novel dendritic cell line | |
| Lee et al. | Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia | |
| JP6522671B2 (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| CN102618498B (zh) | Hla-a0201限制性抗原特异性ctl制备方法 | |
| Ferlazzo et al. | Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells | |
| Ye et al. | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes | |
| US20160208216A1 (en) | Methods of cell culture for adoptive cell therapy | |
| CN120536374A (zh) | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 | |
| Willemen et al. | Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions | |
| Salgaller et al. | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide | |
| KR20210095157A (ko) | 개선된 표현형 속성을 갖는 t 세포 조성물 | |
| Kayser et al. | Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy | |
| Wu et al. | CD19 chimeric antigen receptor–redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide–derived dendritic cell vaccine in leukemia | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells | |
| van Eck van der Sluijs et al. | Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses | |
| CN117580946A (zh) | 用于产生抗原特异性t细胞的方法 | |
| Mason et al. | RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma | |
| Yee | Adoptive therapy using antigen-specific T-cell clones | |
| WO2019217512A1 (en) | Compositions and methods for culturing and expanding cells |